Association between COVID-19 and the incidence of type 1 diabetes in Portugal - a registry study.
COVID-19
Portugal
Type 1 diabetes
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
09 Aug 2024
09 Aug 2024
Historique:
received:
20
11
2023
accepted:
24
07
2024
medline:
10
8
2024
pubmed:
10
8
2024
entrez:
9
8
2024
Statut:
epublish
Résumé
Viral respiratory infections may precipitate type 1 diabetes (T1D). A possible association between the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, and the incidence of T1D is being determined. This study was carried out using Portuguese registries, aiming at examining temporal trends between COVID-19 and T1D. Hospital data, comparing the incidence before and during the COVID-19 pandemic, from children and young adults diagnosed with new-onset T1D, was acquired beginning in 2017 and until the end of 2022. Data was obtained from nine different Portuguese hospital units. The impact of the COVID-19 pandemic, beginning in March 2020, was assessed comparing the annual numbers of new-onset T1D cases. The annual median levels of glucose, glycated hemoglobin (HbA1c) and fasting C-peptide at T1D diagnosis were compared. The annual number of diabetic ketoacidosis (DKA) episodes among new T1D cases was also assessed at two centers. In total, data from 574 newly diagnosed T1D patients was analyzed, including 530 (92.3%) children. The mean ages for child and adult patients were 9.1 (SD 4.4) and 32.8 (SD 13.6) years, respectively. 57.8% (331/573) were male, one patient had unknown sex. The overall median (25-75 percentiles) levels of glucose, HbA1c and fasting C-peptide at diagnosis were 454 mg/dL (356-568), 11.8% (10.1-13.4) and 0.50 µg/L (0.30-0.79), respectively. DKA at T1D diagnosis was present in 48.4% (76/157). For eight centers with complete 2018 to 2021 data (all calendar months), no overall significant increase in T1D cases was observed during the COVID-19 pandemic, i.e. 90 cases in 2018, 90 cases in 2019, 112 in 2020 and 100 in 2021 (P for trend = 0.36). Two of the centers, Faro (CHUA) and Dona Estefânia (CHULC) hospitals, did however see an increase in T1D from 2019 to 2020. No significant changes in glucose (P = 0.32), HbA1c (P = 0.68), fasting C-peptide (P = 0.20) or DKA frequency (P = 0.68) at the time of T1D diagnosis were observed over the entire study period. The T1D incidence did not increase significantly, when comparing the years before and during the COVID-19 pandemic, nor did key metabolic parameters or number of DKA episodes change.
Sections du résumé
BACKGROUND
BACKGROUND
Viral respiratory infections may precipitate type 1 diabetes (T1D). A possible association between the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, and the incidence of T1D is being determined. This study was carried out using Portuguese registries, aiming at examining temporal trends between COVID-19 and T1D.
METHODS
METHODS
Hospital data, comparing the incidence before and during the COVID-19 pandemic, from children and young adults diagnosed with new-onset T1D, was acquired beginning in 2017 and until the end of 2022. Data was obtained from nine different Portuguese hospital units. The impact of the COVID-19 pandemic, beginning in March 2020, was assessed comparing the annual numbers of new-onset T1D cases. The annual median levels of glucose, glycated hemoglobin (HbA1c) and fasting C-peptide at T1D diagnosis were compared. The annual number of diabetic ketoacidosis (DKA) episodes among new T1D cases was also assessed at two centers.
RESULTS
RESULTS
In total, data from 574 newly diagnosed T1D patients was analyzed, including 530 (92.3%) children. The mean ages for child and adult patients were 9.1 (SD 4.4) and 32.8 (SD 13.6) years, respectively. 57.8% (331/573) were male, one patient had unknown sex. The overall median (25-75 percentiles) levels of glucose, HbA1c and fasting C-peptide at diagnosis were 454 mg/dL (356-568), 11.8% (10.1-13.4) and 0.50 µg/L (0.30-0.79), respectively. DKA at T1D diagnosis was present in 48.4% (76/157). For eight centers with complete 2018 to 2021 data (all calendar months), no overall significant increase in T1D cases was observed during the COVID-19 pandemic, i.e. 90 cases in 2018, 90 cases in 2019, 112 in 2020 and 100 in 2021 (P for trend = 0.36). Two of the centers, Faro (CHUA) and Dona Estefânia (CHULC) hospitals, did however see an increase in T1D from 2019 to 2020. No significant changes in glucose (P = 0.32), HbA1c (P = 0.68), fasting C-peptide (P = 0.20) or DKA frequency (P = 0.68) at the time of T1D diagnosis were observed over the entire study period.
CONCLUSION
CONCLUSIONS
The T1D incidence did not increase significantly, when comparing the years before and during the COVID-19 pandemic, nor did key metabolic parameters or number of DKA episodes change.
Identifiants
pubmed: 39123199
doi: 10.1186/s12902-024-01667-5
pii: 10.1186/s12902-024-01667-5
doi:
Substances chimiques
Glycated Hemoglobin
0
Blood Glucose
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
145Informations de copyright
© 2024. The Author(s).
Références
Katsarou A, Gudbjornsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3:17016.
doi: 10.1038/nrdp.2017.16
pubmed: 28358037
Karaoglan M, Eksi F. The coincidence of newly diagnosed type 1 diabetes Mellitus with IgM antibody positivity to enteroviruses and respiratory tract viruses. J Diabetes Res. 2018;2018:8475341.
doi: 10.1155/2018/8475341
pubmed: 30186878
pmcid: 6116462
Lemos JRN, Hirani K, von Herrath M. Immunological and virological triggers of type 1 diabetes: insights and implications. Front Immunol. 2023;14:1326711.
doi: 10.3389/fimmu.2023.1326711
pubmed: 38239343
Filippi CM, von Herrath MG. Viral trigger for type 1 diabetes: pros and cons. Diabetes. 2008;57(11):2863–71.
doi: 10.2337/db07-1023
pubmed: 18971433
pmcid: 2570378
Gerasimidi Vazeou A, Kordonouri O, Witsch M, Hermann JM, Forsander G, de Beaufort C et al. Seasonality at the clinical onset of type 1 diabetes-lessons from the SWEET database. Pediatr Diabetes. 2016;17 Suppl 23:32 – 7.
Patterson CC, Gyurus E, Rosenbauer J, Cinek O, Neu A, Schober E, et al. Seasonal variation in month of diagnosis in children with type 1 diabetes registered in 23 European centers during 1989–2008: little short-term influence of sunshine hours or average temperature. Pediatr Diabetes. 2015;16(8):573–80.
doi: 10.1111/pedi.12227
pubmed: 25316271
World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 . 2023.
Yang L, Han Y, Nilsson-Payant BE, Gupta V, Wang P, Duan X, et al. A human pluripotent stem cell-based platform to Study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell. 2020;27(1):125–36. e7.
doi: 10.1016/j.stem.2020.06.015
pubmed: 32579880
pmcid: 7303620
Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 expression in Pancreas May cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol. 2020;18(9):2128–30. e2.
doi: 10.1016/j.cgh.2020.04.040
pubmed: 32334082
pmcid: 7194639
Unsworth R, Wallace S, Oliver NS, Yeung S, Kshirsagar A, Naidu H, et al. New-Onset type 1 diabetes in children during COVID-19: Multicenter Regional findings in the U.K. Diabetes Care. 2020;43(11):e170–1.
doi: 10.2337/dc20-1551
pubmed: 32816997
Barrett CE, Koyama AK, Alvarez P, Chow W, Lundeen EA, Perrine CG, et al. Risk for newly diagnosed diabetes > 30 days after SARS-CoV-2 infection among persons aged < 18 years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(2):59–65.
doi: 10.15585/mmwr.mm7102e2
pubmed: 35025851
pmcid: 8757617
McKeigue PM, McGurnaghan S, Blackbourn L, Bath LE, McAllister DA, Caparrotta TM, et al. Relation of Incident Type 1 diabetes to recent COVID-19 infection: Cohort Study using e-Health record linkage in Scotland. Diabetes Care. 2023;46(5):921–8.
doi: 10.2337/dc22-0385
pubmed: 35880797
Rahmati M, Keshvari M, Mirnasuri S, Yon DK, Lee SW, Il Shin J, et al. The global impact of COVID-19 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: a systematic review and meta-analysis. J Med Virol. 2022;94(11):5112–27.
doi: 10.1002/jmv.27996
pubmed: 35831242
pmcid: 9350204
D’Souza D, Empringham J, Pechlivanoglou P, Uleryk EM, Cohen E, Shulman R. Incidence of diabetes in children and adolescents during the COVID-19 pandemic: a systematic review and Meta-analysis. JAMA Netw Open. 2023;6(6):e2321281.
doi: 10.1001/jamanetworkopen.2023.21281
pubmed: 37389869
pmcid: 10314307
Reschke F, Lanzinger S, Herczeg V, Prahalad P, Schiaffini R, Mul D, et al. The COVID-19 pandemic affects seasonality, with increasing cases of New-Onset type 1 diabetes in children, from the Worldwide SWEET Registry. Diabetes Care. 2022;45(11):2594–601.
doi: 10.2337/dc22-0278
pubmed: 36166593
Naveed Z, Velasquez Garcia HA, Wong S, Wilton J, McKee G, Mahmood B, et al. Association of COVID-19 infection with Incident Diabetes. JAMA Netw Open. 2023;6(4):e238866.
doi: 10.1001/jamanetworkopen.2023.8866
pubmed: 37071420
pmcid: 10114057
Noorzae R, Junker TG, Hviid AP, Wohlfahrt J, Olsen SF. Risk of type 1 diabetes in children is not increased after SARS-CoV-2 infection: a nationwide prospective study in Denmark. Diabetes Care. 2023;46(6):1261–4.
doi: 10.2337/dc22-2351
pubmed: 37058353
Zareini B, Sorensen KK, Eiken PA, Fischer TK, Kristensen PL, Lendorf ME, et al. Association of Coronavirus Disease 2019 and development of type 1 diabetes: a Danish Nationwide Register Study. Diabetes Care. 2023;46(8):1477–148218.
doi: 10.2337/dc23-0428
pubmed: 37276529
Pereira SM, Barreto FR, de Souza RA, de Souza Teles Santos CA, Pereira M, da Paixao ES, et al. Previous BCG vaccination is associated with less severe clinical progression of COVID-19. BMC Med. 2023;21(1):145.
doi: 10.1186/s12916-023-02859-x
pubmed: 37055776
pmcid: 10099006
Lee HJ, Yu HW, Jung HW, Lee YA, Kim JH, Chung HR, et al. Factors Associated with the Presence and Severity of Diabetic Ketoacidosis at diagnosis of type 1 diabetes in Korean children and adolescents. J Korean Med Sci. 2017;32(2):303–9.
doi: 10.3346/jkms.2017.32.2.303
pubmed: 28049242
Nakhla M, Rahme E, Simard M, Larocque I, Legault L, Li P. Risk of ketoacidosis in children at the time of diabetes mellitus diagnosis by primary caregiver status: a population-based retrospective cohort study. CMAJ. 2018;190(14):E416–21.
doi: 10.1503/cmaj.170676
pubmed: 29632036
pmcid: 5893316
Parkkola A, Harkonen T, Ryhanen SJ, Ilonen J, Knip M, Finnish Pediatric Diabetes R. Extended family history of type 1 diabetes and phenotype and genotype of newly diagnosed children. Diabetes Care. 2013;36(2):348–54.
doi: 10.2337/dc12-0445
pubmed: 23033245
pmcid: 3554291
Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am. 2010;39(3):481–97.
doi: 10.1016/j.ecl.2010.05.011
pubmed: 20723815
pmcid: 2925303
Borges V, Isidro J, Trovao NS, Duarte S, Cortes-Martins H, Martiniano H, et al. SARS-CoV-2 introductions and early dynamics of the epidemic in Portugal. Commun Med (Lond). 2022;2:10.
doi: 10.1038/s43856-022-00072-0
pubmed: 35603268
Canto ECL, Gomes A, Serrano M, Pereira AHG, Ribeiro R, Napoleao P, et al. Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after infection. Eur J Immunol. 2022;52(1):149–60.
doi: 10.1002/eji.202149619
Caetano FB et al. Impact of COVID-19 in New-Onset Type 1 Diabetes Mellitus in a Large Portuguese Pediatric Diabetes Center. Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo. 2022. 17 (3–4).
Kendall EK, Olaker VR, Kaelber DC, Xu R, Davis PB. Association of SARS-CoV-2 infection with New-Onset type 1 diabetes among Pediatric patients from 2020 to 2021. JAMA Netw Open. 2022;5(9):e2233014.
doi: 10.1001/jamanetworkopen.2022.33014
pubmed: 36149658
pmcid: 9508649
Kamrath C, Rosenbauer J, Eckert AJ, Siedler K, Bartelt H, Klose D, et al. Incidence of type 1 diabetes in children and adolescents during the COVID-19 pandemic in Germany: results from the DPV Registry. Diabetes Care. 2022;45(8):1762–71.
doi: 10.2337/dc21-0969
pubmed: 35043145
Patterson CC, Harjutsalo V, Rosenbauer J, Neu A, Cinek O, Skrivarhaug T, et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989–2013: a multicentre prospective registration study. Diabetologia. 2019;62(3):408–17.
doi: 10.1007/s00125-018-4763-3
pubmed: 30483858
Matsuda F, Itonaga T, Maeda M, Ihara K. Long-term trends of pediatric type 1 diabetes incidence in Japan before and after the COVID-19 pandemic. Sci Rep. 2023;13(1):5803.
doi: 10.1038/s41598-023-33037-x
pubmed: 37037893
pmcid: 10085994
European Commision. State of Health in the EU. Portugal Country Health Profile; 2021.
Kamrath C, Rosenbauer J, Eckert AJ, Pappa A, Reschke F, Rohrer TR et al. Incidence of COVID-19 and Risk of Diabetic Ketoacidosis in New-Onset type 1 diabetes. Pediatrics. 2021;148(3).
Salmi H, Heinonen S, Hastbacka J, Laaperi M, Rautiainen P, Miettinen PJ, et al. New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic. Arch Dis Child. 2022;107(2):180–5.
doi: 10.1136/archdischild-2020-321220
pubmed: 34045208
Pietrzak I, Michalak A, Seget S, Bednarska M, Ben-Skowronek I, Bossowski A, et al. Diabetic ketoacidosis incidence among children with new-onset type 1 diabetes in Poland and its association with COVID-19 outbreak-two-year cross-sectional national observation by PolPeDiab Study Group. Pediatr Diabetes. 2022;23(7):944–55.
doi: 10.1111/pedi.13379
pubmed: 35700323
Lokulo-Sodipe K, Moon RJ, Edge JA, Davies JH. Identifying targets to reduce the incidence of diabetic ketoacidosis at diagnosis of type 1 diabetes in the UK. Arch Dis Child. 2014;99(5):438–42.
doi: 10.1136/archdischild-2013-304818
pubmed: 24395643
Giamarellos-Bourboulis EJ, Tsilika M, Moorlag S, Antonakos N, Kotsaki A, Dominguez-Andres J, et al. Activate: Randomized Clinical Trial of BCG vaccination against infection in the Elderly. Cell. 2020;183(2):315–23. e9.
doi: 10.1016/j.cell.2020.08.051
pubmed: 32941801
pmcid: 7462457
Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, et al. Trained immunity: a program of innate immune memory in health and disease. Science. 2016;352(6284):aaf1098.
doi: 10.1126/science.aaf1098
pubmed: 27102489
pmcid: 5087274
Faustman DL, Lee A, Hostetter ER, Aristarkhova A, Ng NC, Shpilsky GF, et al. Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes. Cell Rep Med. 2022;3(9):100728.
doi: 10.1016/j.xcrm.2022.100728
pubmed: 36027906
pmcid: 9376308
Xu E, Xie Y, Al-Aly Z. Risks and burdens of incident dyslipidaemia in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2023;11(2):120–8.
doi: 10.1016/S2213-8587(22)00355-2
pubmed: 36623520
pmcid: 9873268